AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
OCALA, Fla., Aug. 13, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q2 2024 operational and financial results on Friday, August 16, 2024 at 8:30 AM ET.
2024年8月13日佛罗里达州奥卡拉市—— AIm ImmunoTech Inc.（美国纽约证交所：AIM）（“AIM”或“公司”）今日宣布，管理层将于2024年8月16日星期五美国东部时间上午8:30举行电话会议和网络直播，讨论公司2024年第二季度的运营和财务业绩。
The call will be hosted by AIM's Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors section of the Company's website, aimimmuno.com, and will be archived for 90 days following the live event.
电话会议由AIM首席执行官Thomas K. Equels和科学官员Christopher McAleer博士主持，有兴趣的参与者和投资者可以通过拨打（877）407-9219（国内）或（201）689-8852（国际），并提及AIm ImmunoTech会议呼叫来访问电话会议。网络直播将在公司网站aimimmuno.com的投资者部分的“事件”页面上提供，并将在现场直播后90天存档。
About AIM ImmunoTech Inc.
AIM Immunotech股份有限公司是一家免疫药品公司，专注于研究和开发治疗多种癌症、免疫性疾病和病毒性疾病（包括COVID-19）的治疗药物。该公司的主要产品是一种名为Ampligen（吡咯烷寡核苷酸）的首创调节免疫器官的药物，具有广泛的临床试验、覆盖全球重要癌症、病毒性疾病和免疫系统疾病的广谱活性。
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM Immunotech公司是一家免疫药物公司，专注于研究和开发治疗多种癌症、免疫失调和病毒性疾病（包括COVID-19）的治疗药物。该公司的主要产品是一种名为Ampligen（Rintatolimod）的首创性调节免疫药物，是一种dsRNA和高选择性TLR3激动剂，广泛应用于针对全球重要癌症、病毒性疾病和免疫系统疾病的临床试验中。
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
欲了解更多信息，请访问aimimmuno.com，并加入公司的X、LinkedIn和Facebook。
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
投资者联系人：
JTC Team，LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
